<DOC>
	<DOCNO>NCT01641822</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy CAT regimen aztreonam inhalation solution ( AZLI ) tobramycin inhalation solution ( TIS ) adult pediatric subject cystic fibrosis ( CF ) pulmonary Pseudomonas aeruginosa ( PA ) infection . Participants enrol 28 day TIS run-in phase , eligible randomization comparative phase receive non-study oral antibiotic respiratory event , IV inhale antibiotic indication Visits 2 3 , develop condition require hospitalization change clinical status , opinion investigator would preclude ability continue study , demonstrate least 50 % TIS compliance . Participants enrol comparative phase randomize receive 3 cycle treatment , cycle consist alternate regimen : AZLI placebo 28 day follow TIS 28 day .</brief_summary>
	<brief_title>Phase 3 Study Aztreonam Inhalation Solution ( AZLI ) Continuous Alternating Therapy Regimen Treatment Chronic Pseudomonas Aeruginosa Infection Patients With CF</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>Confirmed diagnosis CF Presence PA 2 low respiratory tract culture 12 month prior screen Forced expiratory volume ( FEV ) 1 ≥ 25 ≤ 75 % predict History 1 hospitalization 1 course IV antibiotic acute respiratory exacerbation 12 month prior screen Concurrent use oral , IV inhale antibiotic enrollment Concurrent hospitalization enrollment History local systemic hypersensitivity monobactams aminoglycoside antibiotic history aminoglycoside antibiotic associate toxicity</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>